Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study

Geva, R., Lopez, J.S., Danson, S. orcid.org/0000-0002-3593-2890 et al. (6 more authors) (2018) Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging. ISSN 1619-7070

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Bone metastases; Cancer; Paclitaxel; Radium-223 dichloride; Safety
Dates:
  • Accepted: 3 December 2018
  • Published (online): 13 December 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:
FunderGrant number
SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUSTUNSPECIFIED
Depositing User: Symplectic Sheffield
Date Deposited: 06 Feb 2019 13:29
Last Modified: 06 Feb 2019 13:29
Published Version: https://doi.org/10.1007/s00259-018-4234-6
Status: Published
Publisher: Springer
Refereed: Yes
Identification Number: https://doi.org/10.1007/s00259-018-4234-6
Related URLs:

Share / Export

Statistics